Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2002 Jul;87(1):13–17. doi: 10.1136/adc.87.1.13

The meningococcus tamed?

A Pollard 1, E Moxon 1
PMCID: PMC1751158  PMID: 12089113

Full Text

The Full Text of this article is available as a PDF (115.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ala'Aldeen D. A., Davies H. A., Borriello S. P. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine. 1994 May;12(6):535–541. doi: 10.1016/0264-410x(94)90314-x. [DOI] [PubMed] [Google Scholar]
  2. Baker M., McNicholas A., Garrett N., Jones N., Stewart J., Koberstein V., Lennon D. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. Pediatr Infect Dis J. 2000 Oct;19(10):983–990. doi: 10.1097/00006454-200010000-00009. [DOI] [PubMed] [Google Scholar]
  3. Bartoloni A., Norelli F., Ceccarini C., Rappuoli R., Costantino P. Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine. 1995 Apr;13(5):463–470. doi: 10.1016/0264-410x(94)00007-a. [DOI] [PubMed] [Google Scholar]
  4. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H., Rosenqvist E. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991 Nov 2;338(8775):1093–1096. doi: 10.1016/0140-6736(91)91961-s. [DOI] [PubMed] [Google Scholar]
  5. Boslego J., Garcia J., Cruz C., Zollinger W., Brandt B., Ruiz S., Martinez M., Arthur J., Underwood P., Silva W. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 1995 Jun;13(9):821–829. doi: 10.1016/0264-410x(94)00037-n. [DOI] [PubMed] [Google Scholar]
  6. Cadieux N., Plante M., Rioux C. R., Hamel J., Brodeur B. R., Martin D. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun. 1999 Sep;67(9):4955–4959. doi: 10.1128/iai.67.9.4955-4959.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Carson S. D., Klebba P. E., Newton S. M., Sparling P. F. Ferric enterobactin binding and utilization by Neisseria gonorrhoeae. J Bacteriol. 1999 May;181(9):2895–2901. doi: 10.1128/jb.181.9.2895-2901.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cartwright K., Morris R., Rümke H., Fox A., Borrow R., Begg N., Richmond P., Poolman J. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine. 1999 Jun 4;17(20-21):2612–2619. doi: 10.1016/s0264-410x(99)00044-4. [DOI] [PubMed] [Google Scholar]
  9. Cartwright K., Noah N., Peltola H., Meningococcal Disease Advisory Board Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine. 2001 Aug 14;19(31):4347–4356. doi: 10.1016/s0264-410x(01)00205-5. [DOI] [PubMed] [Google Scholar]
  10. Claassen I., Meylis J., van der Ley P., Peeters C., Brons H., Robert J., Borsboom D., van der Ark A., van Straaten I., Roholl P. Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine. 1996 Jul;14(10):1001–1008. doi: 10.1016/0264-410x(96)00020-5. [DOI] [PubMed] [Google Scholar]
  11. Danve B., Lissolo L., Mignon M., Dumas P., Colombani S., Schryvers A. B., Quentin-Millet M. J. Transferrin-binding proteins isolated from Neisseria meningitidis elicit protective and bactericidal antibodies in laboratory animals. Vaccine. 1993 Sep;11(12):1214–1220. doi: 10.1016/0264-410x(93)90045-y. [DOI] [PubMed] [Google Scholar]
  12. Diermayer M., Hedberg K., Hoesly F., Fischer M., Perkins B., Reeves M., Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain. JAMA. 1999 Apr 28;281(16):1493–1497. doi: 10.1001/jama.281.16.1493. [DOI] [PubMed] [Google Scholar]
  13. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol. 1987 Jun 15;138(12):4402–4407. [PubMed] [Google Scholar]
  14. Frasch C. E., Zahradnik J. M., Wang L. Y., Mocca L. F., Tsai C. M. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J Infect Dis. 1988 Oct;158(4):710–718. doi: 10.1093/infdis/158.4.710. [DOI] [PubMed] [Google Scholar]
  15. Fredriksen J. H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L. O., Lindbak A. K., Møgster B., Namork E., Rye U. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 1991 Dec;14(2):67–80. [PubMed] [Google Scholar]
  16. Fusco P. C., Michon F., Tai J. Y., Blake M. S. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis. 1997 Feb;175(2):364–372. doi: 10.1093/infdis/175.2.364. [DOI] [PubMed] [Google Scholar]
  17. Goldschneider I., Gotschlich E. C., Artenstein M. S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969 Jun 1;129(6):1307–1326. doi: 10.1084/jem.129.6.1307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Granoff D. M., Bartoloni A., Ricci S., Gallo E., Rosa D., Ravenscroft N., Guarnieri V., Seid R. C., Shan A., Usinger W. R. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol. 1998 May 15;160(10):5028–5036. [PubMed] [Google Scholar]
  19. Griffiss J. M., Brandt B. L., Broud D. D., Goroff D. K., Baker C. J. Immune response of infants and children to disseminated infections with Neisseria meningitidis. J Infect Dis. 1984 Jul;150(1):71–79. doi: 10.1093/infdis/150.1.71. [DOI] [PubMed] [Google Scholar]
  20. Gómez J. A., Criado M. T., Ferreirós C. M. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol Med Microbiol. 1998 Jan;20(1):79–86. doi: 10.1111/j.1574-695X.1998.tb01113.x. [DOI] [PubMed] [Google Scholar]
  21. Heath P. T. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J. 1998 Sep;17(9 Suppl):S117–S122. doi: 10.1097/00006454-199809001-00005. [DOI] [PubMed] [Google Scholar]
  22. Johnson A. S., Gorringe A. R., Mackinnon F. G., Fox A. J., Borrow R., Robinson A. Analysis of the human Ig isotype response to lactoferrin binding protein A from Neisseria meningitidis. FEMS Immunol Med Microbiol. 1999 Sep;25(4):349–354. doi: 10.1111/j.1574-695X.1999.tb01359.x. [DOI] [PubMed] [Google Scholar]
  23. Maclennan J. Meningococcal group C conjugate vaccines. Arch Dis Child. 2001 May;84(5):383–386. doi: 10.1136/adc.84.5.383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Martin D., Cadieux N., Hamel J., Brodeur B. R. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med. 1997 Apr 7;185(7):1173–1183. doi: 10.1084/jem.185.7.1173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Milagres L. G., Ramos S. R., Sacchi C. T., Melles C. E., Vieira V. S., Sato H., Brito G. S., Moraes J. C., Frasch C. E. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994 Oct;62(10):4419–4424. doi: 10.1128/iai.62.10.4419-4424.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Munkley A., Tinsley C. R., Virji M., Heckels J. E. Blocking of bactericidal killing of Neisseria meningitidis by antibodies directed against class 4 outer membrane protein. Microb Pathog. 1991 Dec;11(6):447–452. doi: 10.1016/0882-4010(91)90041-8. [DOI] [PubMed] [Google Scholar]
  27. Noronha C. P., Struchiner C. J., Halloran M. E. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int J Epidemiol. 1995 Oct;24(5):1050–1057. doi: 10.1093/ije/24.5.1050. [DOI] [PubMed] [Google Scholar]
  28. Parkhill J., Achtman M., James K. D., Bentley S. D., Churcher C., Klee S. R., Morelli G., Basham D., Brown D., Chillingworth T. Complete DNA sequence of a serogroup A strain of Neisseria meningitidis Z2491. Nature. 2000 Mar 30;404(6777):502–506. doi: 10.1038/35006655. [DOI] [PubMed] [Google Scholar]
  29. Perkins B. A., Jonsdottir K., Briem H., Griffiths E., Plikaytis B. D., Hoiby E. A., Rosenqvist E., Holst J., Nokleby H., Sotolongo F. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis. 1998 Mar;177(3):683–691. doi: 10.1086/514232. [DOI] [PubMed] [Google Scholar]
  30. Pizza M., Scarlato V., Masignani V., Giuliani M. M., Aricò B., Comanducci M., Jennings G. T., Baldi L., Bartolini E., Capecchi B. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000 Mar 10;287(5459):1816–1820. doi: 10.1126/science.287.5459.1816. [DOI] [PubMed] [Google Scholar]
  31. Plested J. S., Ferry B. L., Coull P. A., Makepeace K., Lehmann A. K., MacKinnon F. G., Griffiths H. G., Herbert M. A., Richards J. C., Moxon E. R. Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry. Infect Immun. 2001 May;69(5):3203–3213. doi: 10.1128/IAI.69.5.3203-3213.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Plested J. S., Makepeace K., Jennings M. P., Gidney M. A., Lacelle S., Brisson J., Cox A. D., Martin A., Bird A. G., Tang C. M. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect Immun. 1999 Oct;67(10):5417–5426. doi: 10.1128/iai.67.10.5417-5426.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Poolman J., Berthet F. X. Alternative vaccine strategies to prevent serogroup B meningococcal diseases. Vaccine. 2001 Oct 15;20 (Suppl 1):S24–S26. doi: 10.1016/s0264-410x(01)00283-3. [DOI] [PubMed] [Google Scholar]
  34. Ramsay M. E., Andrews N., Kaczmarski E. B., Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet. 2001 Jan 20;357(9251):195–196. doi: 10.1016/S0140-6736(00)03594-7. [DOI] [PubMed] [Google Scholar]
  35. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001 Mar 21;19(17-19):2688–2691. doi: 10.1016/s0264-410x(00)00554-5. [DOI] [PubMed] [Google Scholar]
  36. Rokbi B., Renauld-Mongenie G., Mignon M., Danve B., Poncet D., Chabanel C., Caugant D. A., Quentin-Millet M. J. Allelic diversity of the two transferrin binding protein B gene isotypes among a collection of Neisseria meningitidis strains representative of serogroup B disease: implication for the composition of a recombinant TbpB-based vaccine. Infect Immun. 2000 Sep;68(9):4938–4947. doi: 10.1128/iai.68.9.4938-4947.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Rosenqvist E., Høiby E. A., Wedege E., Caugant D. A., Frøholm L. O., McGuinness B. T., Brooks J., Lambden P. R., Heckels J. E. A new variant of serosubtype P1.16 in Neisseria meningitidis from Norway, associated with increased resistance to bactericidal antibodies induced by a serogroup B outer membrane protein vaccine. Microb Pathog. 1993 Sep;15(3):197–205. doi: 10.1006/mpat.1993.1070. [DOI] [PubMed] [Google Scholar]
  38. Rosenqvist E., Tjade T., Frøholm L. O., Frasch C. E. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine. NIPH Ann. 1983 Dec;6(2):139–149. [PubMed] [Google Scholar]
  39. Rosenstein N. E., Perkins B. A., Stephens D. S., Lefkowitz L., Cartter M. L., Danila R., Cieslak P., Shutt K. A., Popovic T., Schuchat A. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999 Dec;180(6):1894–1901. doi: 10.1086/315158. [DOI] [PubMed] [Google Scholar]
  40. Sierra G. V., Campa H. C., Varcacel N. M., Garcia I. L., Izquierdo P. L., Sotolongo P. F., Casanueva G. V., Rico C. O., Rodriguez C. R., Terry M. H. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 1991 Dec;14(2):195–210. [PubMed] [Google Scholar]
  41. Stephens D. S., McGee Z. A. Attachment of Neisseria meningitidis to human mucosal surfaces: influence of pili and type of receptor cell. J Infect Dis. 1981 Apr;143(4):525–532. doi: 10.1093/infdis/143.4.525. [DOI] [PubMed] [Google Scholar]
  42. Stuart J. M., Cartwright K. A., Jones D. M., Noah N. D., Wall R. J., Blackwell C. C., Jephcott A. E., Ferguson I. R. An outbreak of meningococcal disease in Stonehouse: planning and execution of a large-scale survey. Epidemiol Infect. 1987 Dec;99(3):579–589. doi: 10.1017/s0950268800066437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sun Y. H., Bakshi S., Chalmers R., Tang C. M. Functional genomics of Neisseria meningitidis pathogenesis. Nat Med. 2000 Nov;6(11):1269–1273. doi: 10.1038/81380. [DOI] [PubMed] [Google Scholar]
  44. Tang C., Moxon R., Levine M. M. For discussion: live attenuated vaccines for group B meningococcus. Vaccine. 1999 Jan;17(2):114–117. doi: 10.1016/s0264-410x(98)00163-7. [DOI] [PubMed] [Google Scholar]
  45. Tappero J. W., Lagos R., Ballesteros A. M., Plikaytis B., Williams D., Dykes J., Gheesling L. L., Carlone G. M., Høiby E. A., Holst J. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999 Apr 28;281(16):1520–1527. doi: 10.1001/jama.281.16.1520. [DOI] [PubMed] [Google Scholar]
  46. Tappero J. W., Lagos R., Ballesteros A. M., Plikaytis B., Williams D., Dykes J., Gheesling L. L., Carlone G. M., Høiby E. A., Holst J. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999 Apr 28;281(16):1520–1527. doi: 10.1001/jama.281.16.1520. [DOI] [PubMed] [Google Scholar]
  47. Tettelin H., Saunders N. J., Heidelberg J., Jeffries A. C., Nelson K. E., Eisen J. A., Ketchum K. A., Hood D. W., Peden J. F., Dodson R. J. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000 Mar 10;287(5459):1809–1815. doi: 10.1126/science.287.5459.1809. [DOI] [PubMed] [Google Scholar]
  48. Tikhomirov E., Santamaria M., Esteves K. Meningococcal disease: public health burden and control. World Health Stat Q. 1997;50(3-4):170–177. [PubMed] [Google Scholar]
  49. Virji M., Makepeace K., Ferguson D. J., Achtman M., Moxon E. R. Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells. Mol Microbiol. 1993 Nov;10(3):499–510. doi: 10.1111/j.1365-2958.1993.tb00922.x. [DOI] [PubMed] [Google Scholar]
  50. Wang J. F., Caugant D. A., Li X., Hu X., Poolman J. T., Crowe B. A., Achtman M. Clonal and antigenic analysis of serogroup A Neisseria meningitidis with particular reference to epidemiological features of epidemic meningitis in the People's Republic of China. Infect Immun. 1992 Dec;60(12):5267–5282. doi: 10.1128/iai.60.12.5267-5282.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. West D., Reddin K., Matheson M., Heath R., Funnell S., Hudson M., Robinson A., Gorringe A. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun. 2001 Mar;69(3):1561–1567. doi: 10.1128/IAI.69.3.1561-1567.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Zollinger W. D., Mandrell R. E., Altieri P., Berman S., Lowenthal J., Artenstein M. S. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis. 1978 Jun;137(6):728–739. doi: 10.1093/infdis/137.6.728. [DOI] [PubMed] [Google Scholar]
  53. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Zollinger W. D., Moran E. E., Devi S. J., Frasch C. E. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun. 1997 Mar;65(3):1053–1060. doi: 10.1128/iai.65.3.1053-1060.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. de Kleijn E. D., de Groot R., Labadie J., Lafeber A. B., van den Dobbelsteen G., van Alphen L., van Dijken H., Kuipers B., van Omme G. W., Wala M. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine. 2000 Feb 14;18(15):1456–1466. doi: 10.1016/s0264-410x(99)00423-5. [DOI] [PubMed] [Google Scholar]
  56. de Kleijn E. D., de Groot R., Lafeber A. B., Labadie J., van Limpt K. C., Visser J., Berbers G. A., van Alphen L., Rümke H. C. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine. 2000 Dec 8;19(9-10):1141–1148. doi: 10.1016/s0264-410x(00)00320-0. [DOI] [PubMed] [Google Scholar]
  57. de Moraes J. C., Perkins B. A., Camargo M. C., Hidalgo N. T., Barbosa H. A., Sacchi C. T., Landgraf I. M., Gattas V. L., Vasconcelos H. de G., Gral I. M. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992 Oct 31;340(8827):1074–1078. doi: 10.1016/0140-6736(92)93086-3. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES